In phase I clinical trials single oral ascending doses (1–300 mg) of AZD3839 were administered to 54 young healthy volunteer.

SH-SY5Y cells (human neuroblastoma cell line) were cultured in DMEM/F-12 with Glutamax, 10% FCS, and 1% nonessential amino acids. The test compound (AZD3839) was incubated with cells for 16 h at 37 °C, 5% CO2. Meso Scale Discovery (MSD) plates were used for the detection of sAPPβ release; MSD sAPPβ plates were blocked in 3% BSA in Tris wash buffer for 1 h at rt and washed four times in Tris buffer. After incubation, 20 μL of medium was transferred to the preblocked and washed 384-well MSD sAPPβ microplate and incubated with shaking at rt for 2 h followed by washing four times in Tris buffer. A 10 μL volume of detection antibody was added (1 nM) followed by incubation with shaking at rt for 2 h followed by washing four times in Tris buffer. A 40 μL volume of read buffer was added per well, and the plates were read in a SECTOR imager. In addition, the cells incubated with test compound were further lysed and analyzed for any cytotoxic effects of the compounds using the ViaLight Plus cell proliferation/cytotoxicity kit